1) Financial Overview and Performance - Revenue for Q2 2026 was $145 million, exceeding guidance and up 2% YoY. - Total revenue for the first half of 2026 reached $0.5 billion, with 31% from the U.S. and 69% from international markets. - The company reported a net loss of $782 million, an improvement of $43 million from the previous year. - Cash and investments at the end of Q2 stood at $6.9 billion, down from $7.5 billion at the end of Q1 2026. - Guidance for 2026 remains at up to 10% revenue growth, with expectations of a 50-50 split between U.S. and international revenue.

2) Pipeline and Product Updates - The seasonal flu vaccine, mRNA-1010, received a positive recommendation from the U.S. VRBPAC, with a PDUFA date set for August 5, 2026. - The norovirus vaccine (mRNA-1403) is preparing to enroll an additional cohort in its Phase III trial after an interim analysis. - In oncology, the Intismeran program continues to show promise, with a 5-year update presented at ASCO 2026. - Dosing has begun in two new cancer antigen therapy programs: mRNA-4194 in Lynch syndrome and mRNA-4200 in solid tumors.

3) Strategic Leadership Changes - Ester Banque has been appointed as the new Chief Commercial Officer, bringing over 30 years of experience in commercial leadership. - Michael McDonnell has joined Moderna's Board of Directors, enhancing the board's expertise in finance and corporate governance.

4) Operational Efficiency and Cost Management - Cash costs were reduced by 10% compared to Q2 2025. - Cost of sales decreased by 22% YoY to $93 million, attributed to improved manufacturing efficiency. - R&D expenses were down 7% YoY to $651 million, reflecting operational efficiencies.

5) Challenges and Future Outlook - The company faces potential declines in COVID vaccination rates, impacting revenue projections. - The Phase III trial for Intismeran in melanoma is ongoing, with interim analysis expected in the second half of 2026. - The transcript lacks specific details on the timing of certain clinical trial readouts and the broader implications of interim results.

Bottom line: Moderna is positioned for growth with a strong pipeline and strategic leadership changes, but faces challenges from declining COVID vaccination rates and ongoing clinical trials. The focus on operational efficiency and cost management is crucial as the company navigates these headwinds while aiming for revenue growth in 2026.